289 related articles for article (PubMed ID: 20021987)
21. [Diagnosis of non-parasitic hypereosinophilia].
Kahn JE; Girszyn N; Blétry O
Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
[TBL] [Abstract][Full Text] [Related]
22. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
23. Pediatric hypereosinophilic syndrome (HES) differs from adult HES.
Katz HT; Haque SJ; Hsieh FH
J Pediatr; 2005 Jan; 146(1):134-6. PubMed ID: 15644839
[TBL] [Abstract][Full Text] [Related]
24. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E; Cools J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
[TBL] [Abstract][Full Text] [Related]
25. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
26. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
Pardanani A; Verstovsek S
Cancer J; 2007; 13(6):384-91. PubMed ID: 18032976
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
28. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.
Klion AD
Hematology Am Soc Hematol Educ Program; 2005; ():209-14. PubMed ID: 16304382
[TBL] [Abstract][Full Text] [Related]
30. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
31. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
[TBL] [Abstract][Full Text] [Related]
32. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
33. Does hypereosinophilic syndrome precede common B acute lymphoblastic leukaemia in childhood? A case report.
Ayhan AC; Timur C; Ayhan Y; Cakır B; Erguven M
Acta Haematol; 2012; 127(2):90-2. PubMed ID: 22156491
[TBL] [Abstract][Full Text] [Related]
34. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
35. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
36. Evaluation and Differential Diagnosis of Persistent Marked Eosinophilia.
Curtis C; Ogbogu PU
Immunol Allergy Clin North Am; 2015 Aug; 35(3):387-402. PubMed ID: 26209891
[TBL] [Abstract][Full Text] [Related]
37. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
38. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
Hellmich B; Holl-Ulrich K; Gross WL
Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
[TBL] [Abstract][Full Text] [Related]
39. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
[TBL] [Abstract][Full Text] [Related]
40. Hypereosinophilic Syndrome.
Curtis C; Ogbogu P
Clin Rev Allergy Immunol; 2016 Apr; 50(2):240-51. PubMed ID: 26475367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
